Clinical Trials Browser

Not yet recruiting × N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide × Clear all

NCT07412262 2026-02-17

A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07339527 2026-01-14

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell

NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

Phase 1/2 Not yet recruiting

Infections, Epstein-Barr Virus Infections

NCT06556862 2025-08-13

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Phase 2 Not yet recruiting

HR+/HER2- Advanced Breast Cancer

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06858956 2025-03-05

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06757387 2025-01-03

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT06682247 2024-11-12

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

Not yet recruiting

Gastrointestinal

Colorectal Cancer Metastatic

NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06218888 2024-01-23

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Phase 2 Not yet recruiting

Gastrointestinal

Colonic Neoplasms